Ischemia-Induced Muscle Myonecrosis, Myoglobinuria, and Secondary Kidney Failure



Ischemia-Induced Muscle Myonecrosis, Myoglobinuria, and Secondary Kidney Failure



Keith C. Menes and Timothy J. Nypaver


Despite many advances in the management of acute limb ischemia, this sudden-onset disease entity continues to have a high morbidity and mortality related both to limb loss and to the development of adverse systemic complications that can lead to renal failure, arrthymia, acute respiratory distress syndrome (shock lung), and death. Improvements in catheter-based delivery of lytic agents have contributed to improved outcomes, but the overall 1-month limb-loss rate remains significant, ranging from 5% to 16%. More alarming are the 1-month mortality rates, ranging from 5% to 12%. This excessive mortality stems from the patient’s underlying chronic comorbidities as well as the systemic complications related to ischemia and reperfusion, namely, ischemia-induced muscle myonecrosis, myoglobinuria, and secondary kidney failure.


Haimovici was the first to recognize the adverse cascade of events that developed with reperfusion of an ischemic extremity and coined the term the myonephropathic-metabolic syndrome. Despite the restoration of arterial flow into a previously ischemic extremity, and paradoxically because of it, patients develop the secondary complications of acidosis, hyperkalemia, rhabdomyolysis, myoglobinuria, and kidney failure, potentially culminating in amputation or death.



Pathophysiology


Regardless of the etiology of the limb ischemia—embolus, thrombosis, or trauma—skeletal muscle ischemia is the inciting event (Box 1). This results in deletion of cellular energy stores within the skeletal muscle cell, leading to impaired cellular ion homeostasis and increased cell membrane permeability. From this ensues an anaerobic process that can ultimately result in cellular dysfunction and death. However, the extent of the injury is not just limited by the ischemic time period. Key to understanding of the concept of ischemia–reperfusion injury is the paradoxical increase in cellular injury associated with reinstitution of blood flow into ischemic tissues. With reperfusion and reintroduction of oxygen, oxygen free radicals form, exacerbating tissue injury and further increasing capillary permeability. Tissue hypoxia also results in the mobilization of neutrophils into the interstitium with potential for deleterious effects upon the endothelial barrier. The increased generation of reactive oxygen metabolites (activated oxygen free radicals) during reperfusion compromises the production of nitric oxide and prostaglandins, favoring vasoconstriction and further limiting overall perfusion.



The local effects of this ischemia–reperfusion injury include fluid sequestration and the development of muscle edema, leading to an increase in pressure within the osteofascial sheath. When the parenchymal interstitial pressure exceeds the capillary perfusion pressure, inadequate tissue perfusion is the result. Untreated or unrecognized, this situation, commonly described as a compartment syndrome, produces cellular death with myonecrosis and permanent neurologic injury. Systemic dissemination of the accumulated byproducts and overrelease of accumulated hydrogen and potassium ions can lead to the metabolic derangements (hyperkalemia, acidosis, and myoglobinuria) associated with ischemia–reperfusion injury. Thus, reoxygenation can have a deleterious effect, and although this effect is highly variable, it primarily depends upon the severity, duration, and extent of ischemia. Histologic evidence of cellular injury can be noted within only 30 minutes of ischemia. Irreversible changes in skeletal muscle occur after 4 to 6 hours of warm ischemia. Within the clinical arena, many factors influence the severity of ischemia, including the acuity of the occlusion, the prior establishment of collateral circulation, the extent of the thrombotic process, and the susceptibility of the tissues to the ischemic insult.


The source of activated oxygen free radicals may be exogenous, from activated neutrophils, or may be produced endogenously, from within the muscle tissue. For skeletal muscle ischemia, the primary endogenous source of oxygen free radicals is the xanthine dehydrogenase–xanthine oxidase pathway. During ischemia, calcium-activated proteases convert the enzyme xanthine dehydrogenase to xanthine oxidase (Figure 1). In the presence of oxygen, now reestablished through reperfusion, hypoxanthine, a byproduct of adenosine triphosphate degradation, is converted by xanthine oxidase to uric acid and the oxygen free radical superoxide. These generated free radicals cause injury through chain reaction lipid peroxidation and inactivation of various cellular enzymes, destabilizing cell membranes.


Stay updated, free articles. Join our Telegram channel

Aug 25, 2016 | Posted by in CARDIOLOGY | Comments Off on Ischemia-Induced Muscle Myonecrosis, Myoglobinuria, and Secondary Kidney Failure

Full access? Get Clinical Tree

Get Clinical Tree app for offline access